Get started
Avalo Therapeutics, Inc.Avalo Therapeutics, Inc.Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AVTX chart


Full chart

AVTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪129.98 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−173.95 USD
Net income (FY)
‪−31.54 M‬ USD
Revenue (FY)
‪1.92 M‬ USD
Shares float
‪9.53 M‬
Beta (1Y)
0.74

Employees


Employees (FY)
19
Change (1Y)
−1 −5.00%
Revenue / Employee (1Y)
‪101.26 K‬ USD
Net income / Employee (1Y)
‪−1.66 M‬ USD

About Avalo Therapeutics, Inc.


Sector
Health Technology
CEO
Garry Arthur Neil
Headquarters
Rockville
Website
avalotx.com
Founded
2011
FIGI
BBG001QHW0Y8
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

AVTX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AVTX is 12.61 USD — it has decreased by −3.66% in the past 24 hours. Watch Avalo Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Avalo Therapeutics, Inc. stocks are traded under the ticker AVTX.
AVTX stock has risen by 2.87% compared to the previous week, the month change is a 35.61% rise, over the last year Avalo Therapeutics, Inc. has showed a −50.88% decrease.
We've gathered analysts' opinions on Avalo Therapeutics, Inc. future price: according to them, AVTX price has a max estimate of 35.00 USD and a min estimate of 35.00 USD. Watch AVTX chart and read a more detailed Avalo Therapeutics, Inc. stock forecast: see what analysts think of Avalo Therapeutics, Inc. and suggest that you do with its stocks.
AVTX reached its all-time high on Feb 27, 2019 with the price of 22,031.71 USD, and its all-time low was 3.95 USD and was reached on Jan 17, 2024. View more price dynamics on AVTX chart.
See other stocks reaching their highest and lowest prices.
AVTX stock is 7.58% volatile and has beta coefficient of 0.74. Track Avalo Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Avalo Therapeutics, Inc. there?
Today Avalo Therapeutics, Inc. has the market capitalization of ‪125.23 M‬, it has decreased by −4.70% over the last week.
Yes, you can track Avalo Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Avalo Therapeutics, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
AVTX earnings for the last quarter are −2.83 USD per share, whereas the estimation was −1.19 USD resulting in a −137.82% surprise. The estimated earnings for the next quarter are −1.06 USD per share. See more details about Avalo Therapeutics, Inc. earnings.
Avalo Therapeutics, Inc. revenue for the last quarter amounts to ‪249.00 K‬ USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
AVTX net income for the last quarter is ‪23.04 M‬ USD, while the quarter before that showed ‪98.46 M‬ USD of net income which accounts for −76.60% change. Track more Avalo Therapeutics, Inc. financial stats to get the full picture.
No, AVTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 19.00 employees. See our rating of the largest employees — is Avalo Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Avalo Therapeutics, Inc. EBITDA is ‪−31.39 M‬ USD, and current EBITDA margin is ‪−1.21 K‬%. See more stats in Avalo Therapeutics, Inc. financial statements.
Like other stocks, AVTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Avalo Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Avalo Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Avalo Therapeutics, Inc. stock shows the sell signal. See more of Avalo Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.